Small Molecules in Hematology

1. Front Matter

   Pages i-viii

   PDF

2. Imatinib Mesylate

   • Cornelius F. Waller

   Pages 1-27

3. Dasatinib

   • Markus Lindauer, Andreas Hochhaus

   Pages 29-68

4. Nilotinib

   • Martin Gresse, Theo D. Kim, Philipp le Coutre

   Pages 69-85

5. Bosutinib: A Potent Second-Generation Tyrosine Kinase Inhibitor

   • Susanne Isfort, Martina Crysandt, Deniz Gezer, Steffen Koschmieder, Tim H. Brümmendorf, Dominik Wolf

   Pages 87-108

6. Ponatinib: A Third-Generation Inhibitor for the Treatment of CML

   • Julius Wehrle, Nikolas von Bubnoff

   Pages 109-118

7. Ruxolitinib

   • Stefanie Ajayi, Heiko Becker, Heike Reinhardt, Monika Engelhardt, Robert Zeiser, Nikolas von Bubnoff et al.

   Pages 119-132

8. Ibrutinib

   • Andriani Charalambous, Mark-Alexander Schwarzbich, Mathias Witzens-Harig

   Pages 133-168

9. Pomalidomide

   • Monika Engelhardt, Stefanie Ajayi, Heike Reinhardt, Stefan Jürgen Müller, Sandra Maria Dold, Ralph Wäsch

   Pages 169-185

10. Enasidenib

    • Alwin Krämer, Tilmann Bochtler

    Pages 187-197

11. Midostaurin: A Multiple Tyrosine Kinases Inhibitor in Acute Myeloid Leukemia and Systemic Mastocytosis

    • Richard F. Schlenk, Sabine Kayser

    Pages 199-214

12. Venetoclax: Targeting BCL2 in Hematological Cancers

    • Annika Scheffold, Billy Michael Chelliah Jebaraj, Stephan Stilgenbauer

    Pages 215-242

13. Idelalisib

    • Katja Zirlik, Hendrik Veelken

    Pages 243-264

14. Carfilzomib

    • Monika Engelhardt, Magdalena Szymaniak-Vits, Stefanie Ajayi, Sandra Maria Dold, Stefan Jürgen Müller, Sophia Scheubeck et al.

    Pages 265-283

15. Acalabrutinib, A Second-Generation Bruton’s Tyrosine Kinase Inhibitor

    • Katharina Kriegsmann, Mark Kriegsmann, Mathias Witzens-Harig

    Pages 285-294

This book, written by respected experts, discusses in detail the latest developments in targeted therapy for hematologic malignancies using small molecules. It covers a wide range of small molecules including tyrosine kinase inhibitors, immunomodulatory drugs, the IDH-2 inhibitor enasidenib, the BCL-2 inhibitor venetoclax, and the proteasome inhibitor carfilzomib. For each molecule, aspects such as the chemical structure, mechanism of action, drug targets, drug interactions, preclinical studies, clinical trials, treatment applications, and toxicity are discussed. 

Extensive research into the molecular mechanisms of cancer has heralded a new age of targeted therapy. The field of precision cancer therapy is now growing rapidly, and the advances being made will mean significant changes in the treatment algorithms for cancer patients. Numerous novel targets that are crucial for the survival of cancer cells can be attacked by small molecules such as protein tyrosine kinase inhibitors. An accompanying volume addresses the use of small molecules in oncology, and the two volumes together represent the third edition of the book originally published under the same title. 

• Small Molecules
• Molecular Mechanisms of Cancer
• Targeted Therapy
• Personalized Cancer Therapy
• Protein Tyrosine Kinease Inhibitors
• mTOR
• Proteasome
• Chemical Structurs
• Drug Interactions
• Treatment Applications

• MOLIT Institute, Cancer Center Heilbronn-Franken, SLK-Clinics, Heilbronn, Germany

  Uwe M. Martens

Uwe Martens, Prof. Dr. med., is chair of the Cancer Center Heilbronn-Franken and head of the Department of Hematology and Oncology at the SLK Clinic Heilbronn, which is an academic teaching hospital of the University of Heidelberg. He graduated in Medicine from the University of Freiburg and continued his medical and scientific training at the Medical University Center in Freiburg and at the BC Cancer Research Center in Vancouver. His scientific focus is the development of personalized cancer therapy and immunotherapy. He is a co-founder of the MOLIT Institute for Personalized Medicine at the science and technology park in Heilbronn, which aims to rapidly translate precision medicine into standard care.

 

Policies and ethics